title: All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/IL-6R system.
abstract: Although high-dose thoracic radiotherapy is an effective strategy for some malignancies including lung cancers and malignant lymphomas, it often causes complications of radiation fibrosis. To study the mechanism initiating tissue fibrosis, we investigated irradiation-induced cytokine production from human lung fibroblastic cells and found that IL-6 production was stimulated by irradiation. IL-6 is an autocrine growth factor for human myeloma cells, and retinoic acid is reported to inhibit their growth. Thus we evaluated the effect of all-trans retinoic acid (ATRA) on cell proliferation of lung fibroblasts along with the cytokine/receptor system. Irradiation-dependent stimulation of IL-6 production was correlated with increased NF-kappaB activity, and ATRA reduced this effect. Irradiation also increased the levels of mRNA for IL-6R and gp130, which were blocked by coexisting ATRA. Furthermore, IL-6 stimulated cell proliferation in dose-dependent manner but was overcome by pharmacological concentration of ATRA. These effects of ATRA were inhibited by rottlerin, which suggests ATRA abolished irradiation-induced stimulation through a PKCdelta-dependent pathway. Finally, we demonstrated that IL-6 transcripts in the lung were upregulated at 2 mo after irradiation, and the effect was inhibited by the intraperitoneal administration of ATRA. ATRA is expected to have an advantage for radiotherapy in its antitumor effects, as reported previously, and to prevent radiotherapy-induced pulmonary injury.
authors.affiliation: Dept. of Respiratory Medicine, Graduate School of Medicine, Kyoto Univ. 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto, Japan 606-8507. ctabata@kuhp.kyoto-u.ac.jp
authors.forename: Chiharu
authors.initials: C
authors.lastname: Tabata
authors.forename: Hajime
authors.initials: H
authors.lastname: Kubo
authors.forename: Rie
authors.initials: R
authors.lastname: Tabata
authors.forename: Manabu
authors.initials: M
authors.lastname: Wada
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Sakuma
authors.forename: Masataka
authors.initials: M
authors.lastname: Ichikawa
authors.forename: Shiro
authors.initials: S
authors.lastname: Fujita
authors.forename: Tadashi
authors.initials: T
authors.lastname: Mio
authors.forename: Michiaki
authors.initials: M
authors.lastname: Mishima
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D050822:Cytokine Receptor gp130 / Q000235:genetics / Q000378:metabolism; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D005720:Gamma Rays; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism*; D008168:Lung / Q000166:cytology* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D019947:Receptors, Interleukin-6 / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D015850:Interleukin-6; D016328:NF-kappa B; D012333:RNA, Messenger; D019947:Receptors, Interleukin-6; D050822:Cytokine Receptor gp130; D014212:Tretinoin